2025³â 12¿ù 20ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research

´º½ºÀÏÀÚ: 2025-06-19

SYDNEY -- Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions.

The Next Frontier explores how biotechnology is addressing some of the world’s most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnership with Tune Therapeutics in advancing a functional cure for Hepatitis B, a chronic disease impacting nearly 300 million people globally. As the global leader in Hepatitis clinical trials, Novotech brings deep therapeutic expertise and global execution capabilities to accelerate development and delivery for sponsors.

Filmed in New Zealand with world-leading hepatologist Professor Edward Gane, where an estimated 100,000 people are living with Hepatitis B, the feature highlights Novotech’s partnership model for supporting biotech and small to mid-size pharma sponsors. It demonstrates how Novotech accelerates clinical development through access to expert investigators, targeted patient populations, and efficient trial infrastructure across Asia-Pacific, Europe, and North America, while showcasing its global capabilities in infectious disease research and trial delivery.

“Our inclusion in this series reflects Novotech’s commitment to supporting innovators with smarter, faster, and more regionally tailored clinical solutions,” said Tom Hickey, Director of Therapeutic Strategy. “Hepatitis B remains a significant global health challenge, and our teams are proud to have such a long history contributing to meaningful progress in this area.”



 Àüü´º½º¸ñ·ÏÀ¸·Î

OpenAI and Capco Partner to Accelerate Transformation in Global Financial Services and Energy
Quectel Takes Smart Meters to the Next Generation at Enlit 2025
Phase 3 Results Position ZIIHERA With TEVIMBRA and Chemo as New First-Line HER2+ Gastric Cancer Standard
GamesBeat Launches New APAC Report: ¡°Creating Opportunities for Video Games in Asia¡± Presented by Xsolla
Riskified Champions Fraud Prevention as a Leading Partner of International Fraud Awareness Week 2025
Wasabi Introduces High-Performance Class and Expands into Silicon Valley to Take on AI¡¯s Rising Data Storage Costs
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

 

LG Business Monitors: Industry-Specific Solutions for Today¡¯s Evolvi...
World No.1 Achievement: AGENCIA¡¯s ¡°360¡ÆCar¢ç¡± Certified by GUINNES...
ASDS 2025: New Data on Restylane, Sculptra, Relfydess Show Galderma¡¯s...
Access Advance Welcomes Xiaomi to HEVC Advance and VVC Advance Patent ...
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Re...
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments fo...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..